Pfizer Inc. has released Quillivant XR, an extended-release liquid medication for attention deficit hyperactivity disorder (ADHD), to U.S. pharmacies.


Pfizer, Quillivant XR, attention deficit hyperactivity disorder, ADHD, ADHD drug, methylphenidate hydrochloride, treatment of ADHD, Sam Azoulay, Ann Childress, Center for Psychiatry and Behavioral Medicine














































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks

Pfizer ships ADHD drug

January 14th, 2013

NEW YORK – Pfizer Inc. has released Quillivant XR, an extended-release liquid medication for attention deficit hyperactivity disorder (ADHD), to U.S. pharmacies.

The pharmaceutical company said Monday that Quillivant XR (methylphenidate hydrochloride) CII is the first once-daily, extended-release liquid methylphenidate for ADHD. It was approved by the  Food and Drug Administration for the treatment of ADHD in patients age 6 and older.

"To effectively treat patients with chronic conditions such as ADHD, it is important to consider individual patient needs, including options for medication administration," commented Ann Childress, M.D., president of the Center for Psychiatry and Behavioral Medicine, Las Vegas, who was an investigator in the Quillivant XR laboratory classroom study. "As the first once-daily, extended-release liquid medication for patients with ADHD, Quillivant XR represents a new alternative to other ADHD treatments."

A central nervous system stimulant prescription drug, Quillivant XR may help increase attention and decrease impulsiveness and hyperactivity in patients with ADHD, according to Pfizer. Although there are many treatment options for ADHD, until Quillivant XR there was no once-daily, extended-release liquid option for the treatment of this condition, the company noted.

"Pfizer is pleased to provide patients and their caregivers with a new option to help manage this challenging condition," stated Sam Azoulay, M.D., senior vice president of medical and development for Pfizer's Emerging Markets and Established Products Business Units. "We also recognize that caring for and treating a child with ADHD goes beyond medication. We look forward to working with mothers and other caregivers of children with ADHD to provide meaningful resources to the ADHD community."

More Supplier News Breaks >>
Advertisement